Table 2.
Multivariate logistic regression of predictors for disease recurrence type*.
| Recurrence-free | Distant metastasis | p | |||
|---|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | ||
| Tumor size | <0.001 | ||||
| >2 cm | 1.0 | 1.0 | |||
| ≤2 cm | 2.13 (1.31–3.48) | 0.002 | 1.12 (0.64–1.97) | 0.686 | |
| Pathological type | 0.182 | ||||
| IDC | 1.0 | 1.0 | |||
| ILC | 1.61 (0.28–9.40) | 0.593 | 2.40 (0.32–18.02) | 0.394 | |
| Other invasive cancer | 2.12 (0.63–7.05) | 0.222 | 1.15 (0.27–4.93) | 0.846 | |
| Histological grade | <0.001 | ||||
| I-II | 1.0 | 1.0 | |||
| III | 0.66 (0.38–1.15) | 0.145 | 0.98 (0.53–1.84) | 0.961 | |
| NA | 0.41 (0.13–1.25) | 0.116 | 0.53 (0.14–2.07) | 0.361 | |
| Lymph node status | 0.048 | ||||
| Negative | 3.24 (1.75–6.02) | <0.001 | 1.82 (0.89–3.73) | 0.103 | |
| Positive | 1.0 | 1.0 | |||
| Molecular subtype | 0.005 | ||||
| Luminal A | 1.0 | 1.0 | |||
| Luminal B HER2− | 0.41 (0.16–1.01) | 0.052 | 0.78 (0.27–2.25) | 0.642 | |
| Luminal B HER2+ | 0.89 (0.23–3.40) | 0.862 | 0.96 (0.21–4.32) | 0.959 | |
| HER2 enriched | 0.34 (0.10–1.20) | 0.094 | 0.55 (0.12–2.48) | 0.440 | |
| TN | 0.52 (0.14–1.88) | 0.316 | 1.30 (0.29–5.87) | 0.730 | |
| Surgery of the breast | <0.001 | ||||
| BCS | 1.0 | 1.0 | |||
| Mastectomy | 3.04 (1.73–5.33) | <0.001 | 3.86 (1.96–7.58) | <0.001 | |
| Surgery of the axilla | <0.001 | ||||
| SLNB | 1.0 | 1.0 | |||
| ALND | 0.84 (0.46–1.51) | 0.552 | 2.80 (1.37–5.75) | 0.005 | |
| Adjuvant chemotherapy | 0.013 | ||||
| No | 1.0 | 1.0 | |||
| Yes | 2.48 (1.37–4.50) | 0.003 | 2.81 (1.37–5.75) | 0.013 | |
| Adjuvant radiotherapy | 0.090 | ||||
| No | 1.0 | 1.0 | |||
| Yes | 1.91 (1.07–3.42) | 0.030 | 2.52 (1.21–5.20) | 0.042 | |
| Adjuvant endocrine therapy | |||||
| No | 1.0 | 1.0 | |||
| Yes | 2.14 (0.94–4.83) | 0.069 | 1.64 (0.62–4.35) | 0.320 | |
OR, odds ratio; CI, confidence interval; LRR, locoregional recurrence; DM, distant metastasis; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; NA, not available; HER2, human epidermal growth factor receptor 2; TN, triple negative; BCS, breast-conserving surgery; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection.
*Reference category was LRR group.